KR20230159650A - 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법 - Google Patents

박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법 Download PDF

Info

Publication number
KR20230159650A
KR20230159650A KR1020237039263A KR20237039263A KR20230159650A KR 20230159650 A KR20230159650 A KR 20230159650A KR 1020237039263 A KR1020237039263 A KR 1020237039263A KR 20237039263 A KR20237039263 A KR 20237039263A KR 20230159650 A KR20230159650 A KR 20230159650A
Authority
KR
South Korea
Prior art keywords
heart failure
ejection fraction
preserved ejection
nrg
neuregulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237039263A
Other languages
English (en)
Korean (ko)
Inventor
밍동 쪼우
Original Assignee
젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 filed Critical 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드
Publication of KR20230159650A publication Critical patent/KR20230159650A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237039263A 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법 Ceased KR20230159650A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201410550212.7 2014-10-17
PCT/CN2015/091459 WO2016058493A1 (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
KR1020177010326A KR102603711B1 (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010326A Division KR102603711B1 (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20230159650A true KR20230159650A (ko) 2023-11-21

Family

ID=55746124

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237039263A Ceased KR20230159650A (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법
KR1020177010326A Active KR102603711B1 (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177010326A Active KR102603711B1 (ko) 2014-10-17 2015-10-08 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법

Country Status (10)

Country Link
US (3) US10561709B2 (https=)
EP (2) EP3207940B1 (https=)
JP (4) JP2017532343A (https=)
KR (2) KR20230159650A (https=)
CN (3) CN111407882A (https=)
AU (2) AU2015333335B2 (https=)
CA (1) CA2963322A1 (https=)
ES (1) ES2924395T3 (https=)
RU (1) RU2017116973A (https=)
WO (1) WO2016058493A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
FI3774859T3 (fi) 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AU2001241839A1 (en) 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7375185B2 (en) 2000-09-12 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
JP2007505158A (ja) 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
WO2006108208A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN106908603B (zh) 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP2370458B1 (en) 2008-11-28 2014-10-15 Zensun (Shanghai) Science and Technology Limited Neuregulin peptides and their use
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
ES2748886T3 (es) * 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
JP6542678B2 (ja) * 2013-03-06 2019-07-10 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物

Also Published As

Publication number Publication date
RU2017116973A (ru) 2018-11-19
KR102603711B1 (ko) 2023-11-20
EP4112068A1 (en) 2023-01-04
AU2015333335A1 (en) 2017-04-20
EP3207940A4 (en) 2018-06-06
US20170232068A1 (en) 2017-08-17
JP2017532343A (ja) 2017-11-02
US10561709B2 (en) 2020-02-18
KR20170066440A (ko) 2017-06-14
US20220354928A1 (en) 2022-11-10
AU2021258063B2 (en) 2025-02-27
WO2016058493A1 (zh) 2016-04-21
RU2017116973A3 (https=) 2019-05-06
AU2021258063A1 (en) 2021-11-25
CN111407882A (zh) 2020-07-14
JP2024164068A (ja) 2024-11-26
EP3207940A1 (en) 2017-08-23
JP2020193217A (ja) 2020-12-03
US20200368317A1 (en) 2020-11-26
EP3207940B1 (en) 2022-06-01
CN105561298A (zh) 2016-05-11
JP2022153417A (ja) 2022-10-12
ES2924395T3 (es) 2022-10-06
CN108064164A (zh) 2018-05-22
CA2963322A1 (en) 2016-04-21
AU2015333335B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
KR102603711B1 (ko) 박출률 보존 심부전을 예방, 치료 또는 지연시키기 위한 뉴레귤린 조성물 및 방법
JP7761964B2 (ja) 心不全の治療用組成物
US20250360078A1 (en) Extended release of neuregulin for treating heart failure
EP3199174B1 (en) Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia
JP2025060703A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
CN117866072A (zh) 神经调节蛋白多肽片段及其用途
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
HK1241737A1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
CN120018856A (zh) 神经调节蛋白及其应用

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231114

Application number text: 1020177010326

Filing date: 20170414

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240520

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250521

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D